Change Password!
Reset Password!
Once-daily use of Upadacitinib 15 mg or 30 mg exhibits superior symptom relief and enhanced quality of life, with rapid and sustained improvements observed across various patient-reported outcomes (such as pain, itching, etc.), starting within 1–2 weeks.
The integrated data from the two clinical trials suggested that Upadacitinib monotherapy rapidly and effectively improved patient-reported outcomes (PROs) in adults and adolescents with AD of moderate-to-severe intensity.
The analysis performed by Eric L. Simpson et al. included 1683 patients (557 receiving Upadacitinib 15 mg, 567 receiving Upadacitinib 30 mg, and 559 receiving placebo given once daily).
A significantly higher proportion of patients on Upadacitinib felt relief from itch (defined as a ≥4-point improvement on the Worst Pruritus Numerical Rating Scale [WP-NRS]) by week 1, with response rates maintained through week 16. Similar improvements were observed in PROs related to skin pain/symptoms, sleep, routine chores, quality of life, emotional state, mental health and patient opinions of disease severity and treatment efficacy.
These improvements were apparent early in the treatment process, with responses typically improving rapidly within 1 to 2 weeks, increasing further by weeks 4–6, which continues through the 16-week assessment period. Overall, the findings suggest that Upadacitinib holds promise in rapidly and effectively improving PROs in individuals with AD.
Dermatology and Therapy
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
Eric L. Simpson et al.
Comments (0)